Company News
MoonLake Completes FDA Pre-BLA, BLA Sep 2026
MoonLake Immunotherapeutics held its final FDA pre‑BLA meeting on April 1, securing acceptance of MIRA trial data and inclusion of VELA‑TEEN data.
Label cites ~43% HiSCR75 response and ~29‑point place
